Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Moderna faces criticism as it prices COVID vaccine at $130 per dose

Pfizer has said it’s considering a similar price for its vaccine.

Fortune

Republicans' COVID vaccine tightrope

Experts say there's a fine line between responsibly scrutinizing policy and fueling misinformation.

Axios

Adding These 2 Stocks to Your Portfolio Could End up Being a Genius Move

Due to still-high inflation and the Fed’s rate hikes, stock market volatility is anticipated to persist. However, fundamentally sound stocks Pfizer (PFE) and Honda Motor (HMC) could be a solid addition to your portfolio. Let's discuss.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Want to Retire a Millionaire? 2 Stocks to Buy Now

The recent bank failures have increased the likelihood of a recession, with many economists increasing the odds of an economic slump in the next 12 months. Amid this backdrop, investors could buy fundamentally strong stocks, Johnson & Johnson (JNJ) and Pfizer (PFE), which could help retire a millionaire. Read on.

StockNews.com

Moderna paid the US more than enough for COVID shot partnership, executive says

WASHINGTON — Moderna Inc. plans to tell U.S. lawmakers that it more than adequately compensated the government for its role in a COVID-19 vaccine partnership that brought the drugmaker billions of dollars, a central point in what’s likely to be a heated Capitol Hill hearing this week.

Tribune News Service

COVID-19 Pill Paxlovid Moves Closer to Full FDA Approval

Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from US health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration. The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021.

Asharq Al-Awsat

COVID-19 pill Paxlovid moves closer to full FDA approval

U.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

4 Robinhood Stocks to Buy Right Now

Zero-commission trading platform Robinhood is highly attractive to Gen Z and millennial investors. Therefore, stocks traded on the Robinhood platform are considered popular and trending. While all Robinhood stocks are not fundamentally sound, Taiwan Semiconductor Manufacturing (TSM), Pfizer (PFE), General Motors (GM), and Nokia (NOK) hold the potential to deliver…

StockNews.com

The Smartest Stock to Buy for Under $50 Now

Pharma giant Pfizer (PFE) had a successful fiscal year 2022 with record-breaking revenue and earnings. Moreover, its recent acquisition should boost its portfolio and revenue. Given the market volatility, this fundamentally strong stock might be an ideal buy for under $50. Keep reading.

StockNews.com

3 Best Stocks to Buy and Hold for a Lifetime

With inflation still alarmingly high, the Fed is poised to raise interest rates further. This is predicted to keep the stock market volatile. Amid this, investors should focus on their long-term strategies and buy fundamentally strong stocks Visa (V), Pfizer (PFE), and Molina Healthcare (MOH), which have solid growth potential.…

StockNews.com

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Tribune News Service

Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

Tribune News Service

Pfizer buys biotech firm Seagen for $43 billion

WASHINGTON - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

Bangkok Post

What the research shows about risks of myocarditis from COVID vaccines versus risks of heart damage from COVID – two pediatric cardiologists explain how to parse the data

Soon after the first COVID-19 vaccines appeared in 2021, reports of rare cases of heart inflammation, or myocarditis, began to surface.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pfizer will spend $43 billion to acquire Seagen

Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday

Inverse

A New Universal Covid-19 Vaccine Could Stop Future Variants in Their Tracks

Here's How a New Covid-19 Vaccine Might Protect Us Against Future Variants

The Independent UK

FDA approves world’s first fast-acting nasal spray to treat migraines

Drug marks ‘significant breakthrough’ for people with migraine who need freedom from pain

Tribune News Service

Pfizer receives FDA approval for migraine nasal spray, claims pain relief in 15 minutes

The U.S. Food and Drug Administration has approved a nasal spray developed by Pfizer as a means to quickly treat the painful symptoms associated with suffering a migraine.

Get all your
news in one place.

100's of premium titles.
One news app.

Manchester Evening News

Greater Manchester's new Covid hotspots revealed as figures show how many in hospital have virus

Around one in 14 of the region's hospital beds are currently occupied by patients with coronavirus

Manchester Evening News

Date confirmed for final Covid vaccines before NHS ends universal offer for good

Health and Social Care Secretary Steve Barclay made the announcement on Wednesday

WEKU

Moderna's COVID vaccine gambit: Hike the price, offer free doses for uninsured

Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.

Evening Standard

What is the UK’s Covid-19 spring booster programme and who is eligible for a vaccine?

London is still lagging behind parts of the country in terms of the vaccine uptake

The Guardian - UK

Vulnerable people in UK to be offered spring Covid booster vaccine

Those eligible are being urged to come forward for the jab as infections remain high across UK

The Independent UK

Covid booster vaccine to be offered to elderly and vulnerable

People aged 75 and over will be offered a vaccination, along with care home residents and anyone aged five and over who is immunosuppressed

Manchester Evening News

Spring Covid-19 booster to be rolled out to vulnerable and elderly

Boosters will be offered around six months on from the previous winter dose

1 … 27 28 29 30

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.